科创板新药第一股鸣钟上交所

Date： 2019-08-12

今早，上海证券交易所科创板新药第一股微芯生物上市仪式举行。中国多层次资本市场从此开启了新的篇章。

微芯生物（股票代码为“688321”）股价首日高开511%。

公司成立于2001年，专注于原创新分子实体药物，覆盖肿瘤、代谢疾病、免疫性疾病三大治疗领域，属于上海证券交易所科创板企业中要求的坚持面向世界科技前沿、符合国家战略、拥有关键核心技术、科技创新能力突出，具有较强成长性的生物医药产业的科技创新企业。

科创板新药第一股鸣钟上交所

微芯生物目前具有14个在研项目储备，其中8个候选药物均为机制新颖的新分子实体。西达本胺片是中国首个以II期临床试验结果获批上市的国家1类原创新药，亦是目前中国唯一治疗外周T细胞淋巴瘤的药物。国家1类新药具有非常高的创新性，基本上代表了我国药品注册分类中药物创新的最高水平。

科创板新药第一股鸣钟上交所

倚锋资本创始人朱晋桥与微芯生物董事长鲁先平博士

科创板新药第一股鸣钟上交所

倚锋资本创始人朱晋桥与蒋华良院士以及投资人合影

微芯生物是国家“创新药物孵化基地”、“国家高新技术企业”，独立承担了多项国家“863“计划、“十五”、“十一五”、“十二五”及“十三五”国家重大科技专项及“重大新药创制”项目。通过技术研发降低了社会医疗成本，突破发达国家在药物领域对中国的技术封锁。本次资金将用于支持未来高质量产品的开发，实现资源的优化配置，通过研发驱动增长的模式提升研发能力，投向科技创新领域。

Previous：China's first new crown oral drug has beNext:No

Related News / Recommended news More

Efung Capital CEO Zhu Pai Attends BIOCHINA 2026: Discussing the New Ecosystem of LP-GP Collaboration

2026 - 03 - 24

In March, Suzhou is gradually embracing the vitality of spring, much like China's biomedical industry, which is gathering momentum amidst transformation. On March 13, during the 11th BioChina Summit (BIOCHINA 2026), Mr. Zhu Pai, CEO of Efung Capital, was invited to attend the core session—the Global Investment Forum—where he engaged in in-depth discussions with industry peers on the theme &quo...

Frontier Biotechnologies Enters Exclusive License Agreement with GSK for siRNA Pipeline Products

2026 - 03 - 25

Frontier Biotechnologies Inc. (“Frontier Biotechnologies” or the “Company”) recently entered into an exclusive licensing agreement with global biopharmaceutical company GlaxoSmithKline (“GSK”). Under the agreement, GSK will obtain exclusive worldwide rights for the development, manufacturing, and commercialization of two siRNA pipeline assets. One candidate drug has reached the Investigational New...

Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio News

2026 - 03 - 06

Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio NewsOn March 5, 2026, the Phase IV clinical study of Oryzogen's recombinant human albumin (rice-derived) Orumin®, evaluating its "safety and efficacy in patients with hypoalbuminemia and/or hypovolemia requiring emergency treatment," achieved its first patient enrollment and completed the init...

Viestar’s Confocal Microscopy Products Selected as Outstanding Domestic Medical Equipment

2026 - 03 - 05

The year 2026 marks the beginning of the 15th Five-Year Plan period. Recently, the 11th batch of the “Outstanding Domestic Medical Equipment Product Catalogue” was officially released. Viestar’s independently developed BIOPSEE® Confocal Laser Endomicroscope and BIOPSEE® Ultra-Thin Probe-based Confocal Laser Endomicroscope were prominently selected. This recognition makes JWS Medical the ...